Exenatide vs Nivolumab

Exenatide vs Nivolumab: Overview

This comparison examines the pharmacological differences between Exenatide and Nivolumab.

Mechanism of Action

Exenatide: Synthetic exendin-4 GLP-1 receptor agonist enhancing glucose-dependent insulin secretion.

Nivolumab: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.

Pharmacokinetics

Half-life: Exenatide — 2.4 hours; Nivolumab — 27 days.

Chemical Properties

Type: Exenatide — Protein; Nivolumab — Antibody.